Drug Trial Radar · NCT00567554
Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Last checked: Nov 19, 2026Latest source record: Feb 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,600
Actual
Start
Oct 2007
Primary completion
Aug 2011
Study completion Oct 2015
Sponsor
- Lead sponsor
- GBG Forschungs GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AGO Study Group
- First posted
- Dec 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Anthracycline-taxane based chemotherapy regimens are recommended mainly by current guidelines for neoadjuvant application of systemic treatment. The addition of other cytotoxic agents, e.g. antimetabolites, vincaalkaloids, or platinum salts resulted in marginal increase in efficacy, but was associated also with an increase in toxicity. Recently, only the addition of the Her-2 antibody trastuzumab has significantly improved pathologic response rate. Therefore, two major strategies are followed in current research projects: * To improve the selection of patients according to their tumors' sensitivity to chemotherapy. * To implement small molecules with specific mechanism of action. Within the GeparQuinto trial, the first strategy is followed by: * The PREDICT substudy. A gene signature specific for the response to anthracyclines and taxanes will be prospectively evaluated for its ability to identify patients with chance higher than 50% for a pCR. The results may leed to a better risk-benefit ratio for the use of conventional chemotherapy. * Adapting further chemotherapy to the response of the tumor to the first couple of chemotherapy cycles. Based on the previous experience made by the GeparTrio study, patients not responding early have a low chance to respond with a pCR irrespective of the type of chemotherapy. So, if further chemotherapy is planned, therapy should be selected according to a favorable toxicity profile. The second strategy is followed by investigating in three parallel group comparisons the efficiency of three distinct small molecules which appear to be generally active in breast cancer: * Bevacizumab, an inhibitor of the VEGF pathway targeting tumor neo-angiogenesis. * Lapatinib, an inhibitor of the Her-1 and Her-2 receptor tyrosine kinase. * RAD001 (Everolimus), an inhibitor of the mTOR molecule, a central controller of tumor cell growth and angiogenesis and chemosensitizer. Treatment for patients participating in the GeparQuinto study will be allocated according to the Her-2 status of the tumor as well as according to the sonographic response after the first 4 cycles of treatment. Experimental therapy with bevacizumab, lapatinib, and everolimus (RAD001) will be randomly added in distinct settings.
Conditions
- Breast Cancer
Interventions
epirubicin - cyclophosphamide / docetaxelDrug
epirubicin - cyclophosphamide / docetaxel + bevacizumabDrug
paclitaxelDrug
paclitaxel + everolimus (RAD001)Drug
epirubicin - cyclophosphamide / docetaxel + trastuzumabDrug
epirubicin - cyclophosphamide / docetaxel + lapatinibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the pCR rates of neoadjuvant treatment in all 3 SettingsTime frame: 2009
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitätsfrauenklinik Frankfurt / Main
Frankfurt am Main, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.